Previous close | 3.0400 |
Open | 3.0550 |
Bid | 2.5200 x 1200 |
Ask | 3.0900 x 800 |
Day's range | 2.8041 - 3.1800 |
52-week range | 0.9550 - 3.3800 |
Volume | |
Avg. volume | 1,477,398 |
Market cap | 68.56M |
Beta (5Y monthly) | 1.19 |
PE ratio (TTM) | N/A |
EPS (TTM) | -1.8860 |
Earnings date | 13 Mar 2023 - 17 Mar 2023 |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | 8.29 |
SOUTH SAN FRANCISCO, Calif., February 01, 2023--Spruce Biosciences, Inc. (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for rare endocrine disorders with significant unmet medical need, today announced that Javier Szwarcberg, M.D., M.P.H., Chief Executive Officer, will present at the SVB Securities Global Biopharma Conference on February 15, 2023, at 2:20 p.m. ET.
When a stock experiences a golden cross technical event, good things could be on the horizon. How should investors react?
SOUTH SAN FRANCISCO, Calif., January 09, 2023--Spruce Biosciences, Inc. (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for rare endocrine disorders with significant unmet medical need, today provided an update on its clinical programs, anticipated upcoming milestones and strategic priorities for advancing tildacerfont in classic congenital adrenal hyperplasia (CAH) and polycystic ovary syndrome (PCOS).